← Back to patent-cliff list
CRN-09682
Tier C — Watch / tradeCRN-09682
Crinetics Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SSTR2, Tubulin
Indications (approved)：Neuroendocrine carcinoma, Neuroendocrine tumour
Regional status
US
Phase II
2025-11-26
EU
Phase II
2025-11-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CRN-09682?
Approved indications include: Neuroendocrine carcinoma, Neuroendocrine tumour.
When does the CRN-09682 patent expire?
No public expiry year is available for CRN-09682 yet; this page updates once verified.
How do I get a quote for CRN-09682 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30